> ## Content Index
> Fetch the complete content index at: https://www.foodconsumer.org/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gcmaf a universal cancer cure?
- URL: https://www.foodconsumer.org/gcmaf_a_universal_cancer_cure_1210161151/
- Published: 2016-12-11T00:47:00.000Z
- Updated: 2026-09-22T16:31:17.000Z
- Description: A comment piece citing studies by Nobuto Yamamoto that report GcMAF, a vitamin D3-binding protein tied to macrophage activation, cured all 16 metastatic prostate cancer patients in a Translational Oncology paper with no recurrence for seven years. It argues immunotherapy avoids drug resistance.
- Author: Food Consumer
- Tags: Drug, Health News, #vivvo-import

**Comment:** *Gcmaf as an immunotherapeutic agent may be used to treat a wide variety of cancers including breast cancer, prostate cancer and colorectal cancer, stomach cancer, liver cancer, lung cancer (including mesothelioma), kidney cancer, bladder cancer, uterus cancer, ovarian cancer, head/neck cancer, brain cancer, and melanoma.*

*The conventional treatments including surgery, chemotherapy and radiation therapy can induce treatment resistance and lead to loss of their efficacy against the cancer they are used to treat. As a result, the recurrence of an even more aggressive or often times lethal cancer is expected to occur in many cases years after the treatments.* 

*One of the best treatments may be immunotherapy like use of Gcmaf, which does not seem to cause drug resistance.*

Nobuto Yamamoto at Socrates Institute for Therapeutic Immunology in Philadelphia, PA and colleagues conducted a series of studies and reported that GcMaf can be used as an immunotherapy to treat cancers like metastatic breast cancer, prostate cancer and colorectal cancer and the efficacy is 100% and no side effects were ever observed.

In a [study ](http://www.sciencedirect.com/science/article/pii/S1936523308800083?ref=foodconsumer.org)published in Translational Oncology, Dr. Yamamoto et al. reported that ALL 16 patients with metastatic prostate cancer were cured after 14 to 25 weeks of administration of GcMaf in a dose of 100 ng/week and no patient had recurrence for seven years.

[GcMaf ](https://immunocentre.eu/what-is-gcmaf/?ref=foodconsumer.org)is a vitamin D3 -binding protein that serves as a precursor to the principal macrophage-activating factor (Maf). GcMaf activity in patients with prostate cancer or other cancers like colorectal cancer and breast cancer was lost or reduced because this protein was deglycosylated by an enzyme released from cancerous cells - nagalase. The deglycosylated protein cannot activate macrophage-activating factor. Gcmaf delivered by IM injection can activate macrophages, which eliminate cancerous cells.

The [study ](http://onlinelibrary.wiley.com/doi/10.1002/ijc.23107/pdf?ref=foodconsumer.org)of Gcmaf as a treatment for 16 metastatic breast cancer was initially published in the International Journal of Cancer but retracted later. The study demonstrated the same efficacy of GcMaf in patients with metastatic breast cancer. The treatment protocol is the same as the one used in the study of prostate cancer and the treatment lasted up to 4 months to cure the disease. No recurrence was observed for four years. 

Another [study ](http://www.gcmaf-therapy.com/wp-content/pdf/Yamamoto,%20Immunotherapy%20of%20metastatic%20colorectal%20Can%20Imm%20Imm%202008.pdf?ref=foodconsumer.org)of GcMaf in treating colorectal cancer demonstrated a similar efficacy. The report was published in Cancer Immunology and Immunotherapy in 2008\. In this study, eight patients with metastatic colorectal cancer experienced the same efficacy and no recurrence was ever observed during the follow-up.

All the patients participating in these studies had had the cancer spread, that is, they had metastatic cancer and also had received conventional treatments. The conventional treatments like surgery, chemotherapy and even radiation therapy are necessary as GcMaf best helps macrophages to eliminate cancerous cells when the tumors are still small, according to [Dr. Tim Smith](http://gcmaf.timsmithmd.com/book/chapter/63/?ref=foodconsumer.org).

The information about the patients does not seem to be complete, according to some critics. For instance, it is unknown whether the reported patients are all or only part of the study cohort. However, some critics acknowledge that even if the patients were cherry-picked to give readers a better impression of the efficacy of Gcmaf, its therapeutic effect is still remarkable. Generally, the survival rate for metastatic cancer is extremely low and often doctors would tell patients there is nothing else they could do to treat their diseases. But GcMaf in these studies does show its long lasting efficacy against metastatic breast cancer, metastatic prostate cancer and metastatic colorectal cancer. 

The United States Food and Drug Administration has not approved gcmaf as a treatment for cancer or any other diseases. Studies also indicated that gcmaf can be effective against autism and viral infections among others. (David Liu)